- Home
- OKYO vs CLNN Comparison
OKYO vs CLNN Comparison
Compare OKYO & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- CLNN
- Stock Information
- Founded
- OKYO 2007
- CLNN 2012
- Country
- OKYO United Kingdom
- CLNN United States
- Employees
- OKYO N/A
- CLNN N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- CLNN Health Care
- Exchange
- OKYO Nasdaq
- CLNN Nasdaq
- Market Cap
- OKYO 37.0M
- CLNN 35.9M
- IPO Year
- OKYO 2022
- CLNN N/A
- Fundamental
- Price
- OKYO $1.19
- CLNN $2.57
- Analyst Decision
- OKYO Strong Buy
- CLNN Strong Buy
- Analyst Count
- OKYO 1
- CLNN 4
- Target Price
- OKYO $7.00
- CLNN $55.25
- AVG Volume (30 Days)
- OKYO 143.7K
- CLNN 53.5K
- Earning Date
- OKYO 04-08-2025
- CLNN 05-07-2025
- Dividend Yield
- OKYO N/A
- CLNN N/A
- EPS Growth
- OKYO N/A
- CLNN N/A
- EPS
- OKYO N/A
- CLNN N/A
- Revenue
- OKYO N/A
- CLNN $342,000.00
- Revenue This Year
- OKYO N/A
- CLNN N/A
- Revenue Next Year
- OKYO N/A
- CLNN $17,399.78
- P/E Ratio
- OKYO N/A
- CLNN N/A
- Revenue Growth
- OKYO N/A
- CLNN N/A
- 52 Week Low
- OKYO $0.81
- CLNN $2.57
- 52 Week High
- OKYO $1.74
- CLNN $9.20
- Technical
- Relative Strength Index (RSI)
- OKYO 45.06
- CLNN 19.09
- Support Level
- OKYO $1.31
- CLNN $3.09
- Resistance Level
- OKYO $1.48
- CLNN $4.66
- Average True Range (ATR)
- OKYO 0.11
- CLNN 0.31
- MACD
- OKYO -0.03
- CLNN -0.16
- Stochastic Oscillator
- OKYO 17.07
- CLNN 0.00
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).